{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"Complete response rate per RECIST Criteria (CTC V3)","groups":[{"description":"Patients undergo hyperfractionated radiotherapy twice daily, 5 days a week, beginning on day 1 and continuing for 6 weeks. Patients also receive fluorouracil IN continuously over 96 hrs. and cisplatin IV continuously over 96 hrs. on days 1-3 and 22-25 and oral gefitinib beginning once daily on day 1 and continuing for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"5-FU, Cisplatin, Radiation and Iressa"}],"paramType":"NUMBER","populationDescription":"5 early deaths were not evaluable","reportingStatus":"POSTED","timeFrame":"3 years","title":"Number of Patients With a Complete Response Defined as Complete Disappearance of All Clinically Detectable Tumor.","type":"SECONDARY","unitOfMeasure":"participants"}